Navigation Links
Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
Date:11/20/2013

NEW YORK, Nov. 20, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech

http://www.reportlinker.com/p01181010/Discovery-Preclinical-and-Clinical-Stage-Partnering-Terms-and-Agreements-in-Pharma-and-Biotech.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the discovery, preclinical and clinical stage partnering deals and agreements entered into by the worlds leading healthcare companies.The report provides a detailed understanding and analysis of how and why companies enter discovery, preclinical and clinical stage partnering deals. The majority of deals are where the licensee obtains a right or an option right to license the licensors product or compound. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.This report contains over 8,000 links to online copies of actual discovery, preclinical and clinical stage deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.The initial chapters of this report provide an orientation of discovery, preclinical and clinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of why companies partner discovery, preclinical and clinical stage compounds/products.Chapter 3 provides an overview of discovery, preclinical and clinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in discovery, preclinical and clinical stage deals.Chapters 5 to 7 provide a review of discovery, preclinical and clinical stage deal making since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.Chapter 8 provides a detailed analysis of discovery, preclinical and clinical stage payment terms including average headline, upfront, milestone and royalty rates for discovery deals.Chapter 9 provides a review of the leading discovery, preclinical and clinical stage deal by headline value.Chapter 10 provides a comprehensive listing of the top 50 big pharma and big biotech companies with a brief summary followed by a comprehensive listing of discovery, preclinical and clinical stage deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.Chapters 11 to 13 provides a comprehensive and detailed review of discovery, preclinical and clinical stage partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.The report also includes numerous tables and figures that illustrate the trends and activities in discovery, preclinical and clinical stage partnering and deal making since 2007.In addition, a comprehensive appendix is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of discovery, preclinical and clinical stage products and compounds.

Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech provides the reader with the following key benefits:

•In-depth understanding of discovery, preclinical and clinical stage deal trends since 2007•Access to headline, upfront, milestone and royalty data•Analysis of the structure of discovery, preclinical and clinical stage agreements with numerous real life case studies•Detailed access to actual discovery, preclinical and clinical stage deals entered into by the leading fifty big pharma and big biotech companies•Insight into the terms included in a discovery, preclinical and clinical stage agreement, together with real world clause examples•Understand the key deal terms companies have agreed in previous deals •Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements Terms and Agreements in Pharm and Biotech is intended to provide the reader with an in-depth understanding and access to discovery, preclinical and clinical stage deal trends and structure of deals entered into by leading companies worldwide.

Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech includes:

•Trends in discovery, preclinical and clinical stage dealmaking in the biopharma industry since 2007•Analysis of discovery, preclinical and clinical stage deal structure•Access to headline, upfront, milestone and royalty data•Case studies of real-life discovery, preclinical and clinical stage deals•Access to over 8,000 discovery, preclinical and clinical stage deals•The leading discovery, preclinical and clinical stage deals by value since 2007•Most active discovery, preclinical and clinical stage dealmakers since 2007•The leading discovery, preclinical and clinical stage partnering resources

In Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharm and Biotech, the available contracts are listed by:
•Company A-Z

•Headline value

•Stage of development at signing

•Deal type

•Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.The Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and biotech report provides comprehensive access to available deals and contract documents for over 8,000 discovery, preclinical and clinical stage deals.

Analyzing actual contract agreements allows assessment of the following:

•What are the precise rights granted or optioned?•What is actually granted by the agreement to the partner company?•What exclusivity is granted?•What is the payment structure for the deal?•How aresalesand payments audited?•What is the deal term?•How are the key terms of the agreement defined?•How are IPRs handled and owned?•Who is responsible for commercialization?•Who is responsible for development, supply, and manufacture?•How is confidentiality and publication managed?•How are disputes to be resolved?•Under what conditions can the deal be terminated?•What happens when there is a change of ownership?•What sublicensing and subcontracting provisions have been agreed?•Which boilerplate clauses does the company insist upon?•Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?

Which jurisdiction does the company insist upon for agreement law?

Executive SummaryChapter 1 – IntroductionChapter 2 – Why do company's partner discovery, preclinical and clinical stage compounds?2.1. Introduction

2.2. The role of discovery, preclinical and clinical stage partnering

2.2.1. In-licensing at clinical stage

2.2.2. Out-licensing at discovery stage

2.2.3. Out-licensing at clinical stage

2.3. Difference between discovery, preclinical and clinical stage deals

2.4. Reasons for entering into discovery, preclinical and clinical stage partnering deals

2.4.1. Licensors reasons for entering discovery, preclinical and clinical stage deals

2.4.2. Licensees reasons for entering discovery, preclinical and clinical stage deals

2.5. The future of discovery, preclinical and clinical stage partnering deals




Chapter 3 – Discovery, preclinical and clinical stage deal strategies and structure

3.1. Introduction

3.2. At what stage do companies partner?

3.2.1. Partnering early in pharmaceutical/biotech

3.2.1.1. Discovery and preclinical stage partnering case studies

3.2.1.1.a. Case study: LEO Pharma - 4SC

3.2.1.1.b. Case study: Heptares Therapeutics - Cubist

3.2.1.1.c. Case study: Pfizer - Repligen

3.2.1.1.d. Case study: Janssen Pharmaceutical - Evotec

3.2.2. Partnering later in pharmaceutical/biotech

3.2.2.1. Clinical stage partnering case studies

3.2.2.1.a. Case study: Roche – Genentech - Chiasma

3.2.2.1.b. Case study: Teva – Xenon Pharmaceuticals

3.2.2.1.c. Case study: AstraZeneca - Ardelyx

3.2.2.1.d. Case study: Baxter – Onconova Therapeutics

3.3. Early and later stage partnering – a risk/cost comparison

3.4. What do companies spend on discovery, preclinical and clinical stage partnering?

3.5. Pure versus multi-component partnering deals

3.6. Pure licensing agreement structure

3.6.1. Example pure licensing agreements

3.6.1.a. Case study : Coley Pharmaceutical – Dynavax Technologies

3.6.1.b. Case study : Bristol-Myers Squibb - Pharmacopeia

3.7. Multicomponent partnering agreements

3.7.1. Example multicomponent deal clauses

3.7.1.a. Case study: Idera – Merck KGaA

Chapter 4 – Discovery, preclinical and clinical stage partnering payment strategies

4.1. Introduction

4.2. Discovery, preclinical and clinical stage payment strategies

4.3. Payment options

4.3.1. Headline values

4.3.2. Upfront payments

4.3.2.1. Conditionality of upfront payments

4.3.3. Loans

4.3.4. Convertible loans

4.3.5. Equity

4.3.6. R&D funding

4.3.7. Licensing fees

4.3.8. Milestone payments

4.3.9. Royalty payments

4.3.9.1. Issues affecting royalty rates

4.3.9.2. Royalties on combination products

4.3.9.2.a. Case study: Scripps Research Institute-Cyanotech

4.3.9.3. Guaranteed minimum/maximum annual payments

4.3.9.4. Royalty stacking

4.3.9.5. Royalties and supply/purchase contracts

4.3.10. Quids

4.3.11. Option payments

Chapter 5 – Trends in discovery stage deal making

5.1. Introduction

5.2. Discovery stage partnering over the years

5.2.1. Attributes of discovery deals

5.3. Big pharma discovery stage dealmaking activity

5.4. Big biotech discovery stage dealmaking activity

5.5. Discovery stage partnering by deal type

5.6. Discovery stage partnering by disease type

5.7. Partnering by discovery stage technology typeChapter 6 – Trends in preclinical stage deal making6.1. Introduction

6.2. Preclinical stage partnering over the years

6.2.1. Attributes of preclinical deals

6.3. Big pharma preclinical stage dealmaking activity

6.4. Big biotech preclinical stage dealmaking activity

6.5. Preclinical stage partnering by deal type

6.6. Preclinical stage partnering by disease type

6.7. Partnering by preclinical stage technology type

Chapter 7 – Trends in clinical stage deal making7.1. Introduction

7.2. Clinical stage partnering over the years

7.2.1. Trends in phase I deals since 2007

7.2.1.1. Attributes of phase I deals

7.2.2. Trends in phase II deals since 2007

7.2.2.2. Attributes of phase II deals

7.2.3. Trends in phase III deals since 2007

7.2.3.1. Attributes of phase III deals

7.3. Big pharma clinical stage dealmaking activity

7.4. Big biotech clinical stage dealmaking activity

7.5. Clinical stage partnering by deal type

7.6. Clinical stage partnering by disease type

7.7. Partnering by clinical stage technology type



Chapter 8 – Average payment terms for discovery, preclinical and clinical stage partnering

8.1. Introduction

8.2. Guidelines for discovery, preclinical and clinical stage payment terms

8.2.1. Upfront payments

8.2.2. Milestone payments

8.2.3. Royalty payments

8.3. Discovery, preclinical and clinical stage payment terms – deal data analysis

8.3.1. Public data

8.3.2. Survey data

8.4. Payment terms analysis

8.4.1. Discovery, preclinical and clinical stage headline values

8.4.2. Discovery, preclinical and clinical stage upfront payments

8.4.3. Discovery, preclinical and clinical stage milestone payments

8.4.4. Discovery, preclinical and clinical stage royalty ratesChapter 9 – Leading discovery, preclinical and clinical stage deals9.1. Introduction

9.2. Top discovery stage deals by value

9.3. Top preclinical stage deals by value

9.4. Top clinical stage deals by value

Chapter 10 – Big pharma and big biotech discovery, preclinical and clinical stage partnering deals

10.1. Introduction

10.2. How to use big pharma/big biotech partnering deals

10.3. Big pharma discovery, preclinical and clinical stage partnering company profiles

Abbott

Actavis (merged with Watson Pharmaceuticals Oct 2012)

Actelion

Allergan

Amgen

Aspen Pharmacare

Astellas

AstraZeneca

Baxter International

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

CSL

Daiichi Sankyo

Dainippon Sumitomo

Eisai

Eli Lilly

Endo Pharmaceuticals

Forest Laboratories

Galderma

Gilead Sciences

GlaxoSmithKline

Grifols

Hospira

Johnson & Johnson

Kyowa Hakko Kirin

Lundbeck

Menarini

Merck & Co

Merck KGaA

Mitsubishi Tanabe

Mylan

Novartis

Novo Nordisk

Otsuka

Pfizer

Purdue

Roche

Sanofi

Servier

Shionogi

Shire

Takeda

Teva

UCB

Valeant

Warner Chilcott10.4. Big biotech clinical stage partnering company profiles

Acorda Therapeutics

Actelion

Alexion Pharmaceuticals

Alkermes

Alnylam Pharmaceuticals

AMAG Pharmaceuticals

Amgen

Amylin Pharmaceuticals

Anika Therapeutics

Bavarian Nordic

Biocon

BioCryst Pharmaceuticals

Biogen Idec

BioMarin Pharmaceuticals

Biota Holdings

Cangene

Celgene

CSL

Cubist

Elan

Emergent BioSolutions

Enzo Biochem

Enzon Pharmaceuticals

Exelixis

Genmab

Gilead Sciences

Immunomedics

Intermune

Isis Pharmaceuticals

Morphosys

Nektar Therapeutics

NPS Pharmaceuticals

Onyx Pharmaceuticals

PDL BioPharma

Questcor Pharmaceuticals

Regeneron Pharmaceuticals

Roche

SciClone Pharmaceuticals

Seattle Genetics

Spectrum Pharmaceuticals

Targacept

The Medicines Company

UCB

United Therapeutics

Vertex Pharmaceuticals

ViroPharmaChapter 11 – Discovery stage partnering contracts directory

11.1. Introduction

11.2. Company A-Z

11.3. By deal type

11.4. By stage of development

11.5. By therapy area

Chapter 12 – Preclinical stage partnering contracts directory

12.1. Introduction

12.2. Company A-Z

12.3. By deal type

12.4. By stage of development

12.5. By therapy area

Chapter 13 – Clinical stage partnering contracts directory

13.1. Introduction

13.2. Company A-Z

13.3. By deal type

13.4. By stage of development

13.5. By therapy area

About Wildwood Ventures

Current Partnering

Current Agreements

Recent titles from Current Partnering

Order Form – Reports

Order Form – Reports

Order Form – Therapy ReportsAppendices

Introduction

Appendix 1 – Directory of discovery stage deals by company A-Z 2007-2013

Appendix 2 – Directory of discovery stage deals by deal type 2007-2013

Appendix 3 – Directory of discovery stage deals by therapy area 2007-2013

Appendix 4 – Directory of preclinical stage deals by company A-Z 2007-2013

Appendix 5 – Directory of preclinical stage deals by deal type 2007-2013

Appendix 6 – Directory of preclinical stage deals by therapy area 2007-2013

Appendix 7 – Directory of clinical stage deals by company A-Z 2007-2013

Appendix 8 – Directory of clinical stage deals by deal type 2007-2013

Appendix 9 – Directory of clinical stage deals by therapy area 2007-2013

Appendix 10 – Partnering resource center

Online partnering

Partnering events

Further reading on dealmaking

?

Table of figures

Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking

Figure 2: Agreements signed by phase of development (2007-2013), % of all deals

Figure 3: Components of the pure licensing deal structure

Figure 4: Payment options for discovery, preclinical and clinical stage partnering deals

Figure 5: Issues affecting royalty rates

Figure 6: Discovery stage partnering frequency 2007-2013

Figure 7: Big pharma – top 50 – discovery stage deals 2007 to 2013

Figure 8: Big pharma discovery stage deal frequency – 2007 to 2013

Figure 9: Big biotech – top 50 – discovery stage deals 2007 to 2013

Figure 10: Big biotech discovery stage deal frequency – 2007 to 2013

Figure 11: Discovery stage partnering by deal type since 2007

Figure 12: Discovery stage partnering by disease type since 2007

Figure 13: Discovery stage partnering by technology type since 2007

Figure 14: Preclinical stage partnering frequency 2007-2013

Figure 15: Big pharma – top 50 – preclinical stage deals 2007 to 2013

Figure 16: Big pharma preclinical stage deal frequency – 2007 to 2013

Figure 17: Big biotech – top 50 – preclinical stage deals 2007 to 2013

Figure 18: Big biotech preclinical stage deal frequency – 2007 to 2013

Figure 19: Preclinical stage partnering by deal type since 2007

Figure 20: Preclinical stage partnering by disease type since 2007

Figure 21: Preclinical stage partnering by technology type since 2007

Figure 22: Clinical stage partnering frequency 2007-2013

Figure 23: Phase I clinical stage partnering since 2007

Figure 24: Phase II clinical stage partnering since 2007

Figure 25: Phase III clinical stage partnering since 2007

Figure 26: Big pharma – top 50 – clinical stage deals 2007 to 2013

Figure 27: Big pharma clinical stage deal frequency – 2007 to 2013

Figure 28: Big biotech – top 50 – clinical stage deals 2007 to 2013

Figure 29: Big biotech clinical stage deal frequency – 2007 to 2013

Figure 30: Clinical stage partnering by deal type since 2007

Figure 31: Clinical stage partnering by disease type since 2007

Figure 32: Clinical stage partnering by technology type since 2007

Figure 33: Review of upfront payments for discovery, preclinical and clinical stage deals, US$m

Figure 34: Review of milestone payments for discovery, preclinical and clinical stage deals, US$m

Figure 35: Review of royalty payments for clinical stage deals, %

Figure 36: Discovery, preclinical and clinical stage deals with a headline value

Figure 37: Discovery stage deal headline value distribution, US$million – phase I stage

Figure 38: Preclinical stage deal headline value distribution, US$million – phase I stage

Figure 39: Clinical stage deal headline value distribution, US$million – phase I stage

Figure 40: Clinical stage deal headline value distribution, US$million – phase II stage

Figure 41: Clinical stage deal headline value distribution, US$million – phase III stage

Figure 42: Summary median headline value by stage of development, 2007-2013

Figure 43: Discovery, preclinical and clinical stage deals with upfront payment values

Figure 44: Discovery stage deal upfront payment distribution, US$million

Figure 45: Preclinical stage deal upfront payment distribution, US$million

Figure 46: Clinical stage deal upfront payment distribution, US$million – phase I stage

Figure 47: Clinical stage deal upfront payment distribution, US$million – phase II stage

Figure 48: Clinical stage deal upfront payment distribution, US$million – phase III stage

Figure 49: Summary median upfront payments by stage of development, 2007-2013

Figure 50: Discovery, preclinical and clinical stage deals with milestone payments

Figure 51: Discovery stage deal milestone distribution, US$million

Figure 52: Preclinical stage deal milestone distribution, US$million

Figure 53: Clinical stage deal milestone distribution, US$million – phase I stage

Figure 54: Clinical stage deal milestone distribution, US$million – phase II stage

Figure 55: Clinical stage deal milestone distribution, US$million – phase III stage

Figure 56: Summary median milestone payments by stage of development, 2007-2013

Figure 57: Discovery, preclinical and clinical stage deals with royalty rates, %

Figure 58: Discovery stage deal royalty rate distribution, US$million

Figure 59: Preclinical stage deal royalty rate distribution, US$million

Figure 60: Clinical stage deal royalty rate distribution, US$million – phase I stage

Figure 61: Clinical stage deal royalty rate distribution, US$million – phase II stage

Figure 62: Clinical stage deal royalty rate distribution, US$million – phase III stage

Figure 63: Summary median royalty rate by stage of development, 2007-2013

Figure 64: Top discovery stage deals by value since 2007

Figure 65: Top preclinical stage deals by value since 2007

Figure 66: Top clinical stage deals by value since 2007




Companies mentioned

Abbott Japan

Abbott Laboratories

Abraxis BioScience

ACADIA Pharmaceuticals

Acceleron Pharma

Achillion Pharmaceuticals

Adnexus Therapeutics

Adolor

AEterna Zentaris

Affymax

Agensys

Alfacell

Allergan

Ambit Biosciences

Amgen

Amylin Pharmaceuticals

Anacor Pharmaceuticals

Anesiva

Archemix

Ariad Pharmaceuticals

ArQule

Array Biopharma

ARYx Therapeutics

Astellas Pharma

AstraZeneca

Athersys

Atley Pharmaceuticals

Auriga Laboratories

Aventis

AVEO Pharmaceuticals

Barrier Therapeutics

Bayer

Biogen Idec

BioMarin Pharmaceuticals

BioMerieux

Biovail

Boehringer Ingelheim

Bristol-Myers Squibb

Cardiome Pharma

Celgene

Cell Genesys

Cepheid

ChemoCentryx

Cornerstone Biopharma

Cortex Pharmaceuticals

Critical Therapeutics

Cubist Pharmaceuticals

CV Therapeutics

Cypress Bioscience

Cytokinetics

Daiichi Sankyo

DepoMed

Dey Pharma

DoctorDirectory

DOR BioPharma

Dyax

Dynavax Technologies

Eisai

Eli Lilly

Enanta Pharmaceuticals

Endo Pharmaceuticals

Exelixis

Facet Biotechnology

Forest Laboratories

Forest Pharmaceuticals

Galderma

Genentech

Genzyme

Gilead Sciences

GlaxoSmithKline

GTx

Hyperion Therapeutics

ImmunoGen

Immunomedics

Impax Laboratories

Incyte

Inspire Pharmaceuticals

InterMune

InVentiv Health

Ipsen

Ironwood Pharmaceuticals

Janssen Research & Development

KaloBios Pharmaceuticals

La Jolla Pharmaceutical

Macrogenics

MAP Pharmaceuticals

Maxygen

Medivation

Menarini

Merck and Co

Merck KGaA

Merck Sharpe & Dohme

Merrimack Pharmaceuticals

Metabasis Therapeutics

Micromet

MiddleBrook Pharmaceutical

Millennium

Mylan Laboratories

Nektar Therapeutics

Novartis

Novartis Consumer Health

Novo Nordisk

Nycomed

OncoGenex Pharmaceuticals

Optimer Pharmaceuticals

Orexigen Therapeutics

Ortho Biotech

Par Pharmaceutical

PDL BioPharma

Pfizer

PhotoMedex

Procter & Gamble

Procter & Gamble Pharmaceuticals

Purdue Pharma

Regeneron Pharmaceuticals

Rib-X Pharmaceuticals

Roche

Sagent Pharmaceuticals

Salix Pharmaceuticals

Sanofi-Aventis

Sanofi-Pasteur

Sanofi

Santarus

Schering-Plough

Seattle Genetics

Serono

Sigma-Tau

Solvay

Somaxon Pharmaceuticals

Spectrum Pharmaceuticals

Strativa Pharmaceuticals

Sucampo Pharmaceuticals

Synta Pharmaceuticals

Takeda Pharmaceutical

TAP Pharmaceutical

Targacept

Tercica

Teva Pharmaceuticals

Tibotec

Transcept Pharmaceuticals

Ucyclyd Pharma

Valeant Pharmaceuticals

Veracyte

Vernalis

Vical

Victory Pharma

Warner Chilcott

Watson Pharmaceuticals

Wyeth

Xenoport

Zogenix

ZymoGenetics

To order this report: Discovery, Preclinical and Clinical Stage Partnering Terms and Agreements in Pharma and Biotech
http://www.reportlinker.com/p01181010/Discovery-Preclinical-and-Clinical-Stage-Partnering-Terms-and-Agreements-in-Pharma-and-Biotech.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

__________________________
Contact Clare: clare@reportlinker.com
US: (339)-368-6001
Intl: +1 339-368-6001







'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved


Related medicine technology :

1. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
2. Regulus Therapeutics Forms Strategic Alliance for Discovery, Development and Commercialization of microRNA Therapeutics with AstraZeneca
3. Antigen Discovery, Inc. Awarded Phase II SBIR Grant to Identify Biomarkers Associated with Protection against Malaria
4. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
5. Regulus Presents Positive Preclinical Data Demonstrating that microRNA-21 Plays an Important Role in Alport Syndrome
6. Positive Preclinical Profile of RG-101, a GalNAc-conjugated anti-miR Targeting microRNA-122, Supports Clinical Development for the Treatment of HCV
7. Data Presented For ENMD-2076 In Preclinical Models Of Triple-Negative Breast Cancer
8. MicroConstants Expands Biomarker Testing and Analysis Services for Preclinical and Clinical Diagnostic Research
9. Lexicon Presents Preclinical Data On LX2761, a New Clinical Candidate for Diabetes Designed to Reduce Glucose Absorption From Gastrointestinal Tract
10. Tumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer Preclinical Models with Addition of Galectin Inhibitor
11. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016 Potrero Medical, Inc., the ... to announce the appointment of George M. Rapier, III ... San Antonio, TX , WellMed is one of the ... patients and HMO members in Texas ... 1990 out of his own internal medicine practice, he has ...
(Date:2/11/2016)...  MiMedx Group, Inc. (NASDAQ: MDXG ), the ... other birth tissues, human skin and bone, and patent-protected ... products and therapies, announced today that it will present ... in New York , NY.  Parker ... Senken , Chief Financial Officer and Chris Cashman ...
(Date:2/11/2016)... , Feb. 11, 2016  AfterPill.com is reporting ... recommend alcohol abstinence for all women who are at ... the U.S. each year and raises the risks of ... --> According to the Guttmacher Institute, ... of women of child-bearing age, who have sex without ...
Breaking Medicine Technology:
(Date:2/13/2016)... Coral Springs, FL (PRWEB) , ... February 13, 2016 , ... ... on the environmental impact of American businesses. , The increasingly modern world of ... rely more often on non-renewable energy sources such as oil and coal, which pollutes ...
(Date:2/13/2016)... Canada (PRWEB) , ... February 13, 2016 , ... In ... foot forward. They’ll groom themselves to perfection, go out of their way to be ... date – just take a look at any online dating profile. , A ...
(Date:2/12/2016)... ... February 12, 2016 , ... The law firm of Morrow, ... Parishes. The purpose of these scholarships is to encourage applicants to pursue a ... seek employment within these two parishes. , “We have available jobs in St. ...
(Date:2/12/2016)... Falls Church, VA (PRWEB) , ... February 12, ... ... in Store?, Feb. 29, 2016 — 1:30 p.m. – 3:00 p.m. EST, ... burner issue in the life cycle of pharmaceutical products, garnering increased attention from ...
(Date:2/12/2016)... ... February 12, 2016 , ... T.E.N., a technology and information ... ISE Southeast Awards 2016. Finalists and winners of the ISE® Awards for both ... and Awards Gala on March 15, 2016 at the Westin Peachtree Plaza, Atlanta. ...
Breaking Medicine News(10 mins):